Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of RVT-101 in dementia with Lewy bodies
2016-002412-40Phase 2Terminated
- Sponsor
- Sio Gene Therapies
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of intepirdine in dementia with Lewy bodies (DLB) (2 arms), sponsored by Sio Gene Therapies. Primary endpoint: Incidence of adverse events and safety/tolerability assessments. Started Oct 2016; status: terminated.
02
Drugs
intepirdine
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on 2016-002412-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002412-40.